Gupta Ruchi, Mishra Neelima, Kumar Ashwani, Rana Roma, Srivastava Bina, Tyagi P K, Anvikar Anupkumar R, Valecha Neena
National Institute of Malaria Research, Sector 8, Dwarka, New Delhi, 110077, India.
Parasitol Res. 2015 Sep;114(9):3487-96. doi: 10.1007/s00436-015-4577-x. Epub 2015 Jun 27.
Antimalarial drug resistance including artemisinin resistance in Plasmodium falciparum malaria is a major concern in combating malaria throughout the world. Delayed parasite clearance time (PCT) is indicative of emergence of artemisinin resistance. Herein, PCT has been monitored with the help of gold standard technique microscopy accompanied by a more sensitive real-time assay for academic purpose. After the administration of artemisinin based combination therapy, artesunate + sulfadoxine pyrimethamine (AS + SP), all the subjects were followed up to day 42 for monitoring the therapeutic efficacy of AS + SP in Bisra Community Health Centre (CHC), Sundergarh district in the state of Odisha in India. Further, representative samples were analyzed for L263E, E431K, A623E and S769N SNPs in Pfatpase6 gene and copy number polymorphisms in Pfmdr1 gene. Though all the samples were found parasite negative according to microscopy by the end of day 3 and attained adequate clinical and parasitological response (ACPR) at the end of day 42, real-time PCR showed day 3 positivity in 12 of the total analyzed samples (n = 43). This was further validated by end-point diagnostic PCR and correlated with high initial parasite load. E431K mutation was observed in 2 of the 12 samples (16.7 %) while the controls (n = 18) were all wild. L263E, A623E and S769N were wild in all the analyzed samples (n = 30). Pfmdr1 copy number analysis showed no change in the said trait. Conclusively, real-time PCR could support microscopy for better monitoring of PCT and may provide as an additional but useful research tool for artemisinin resistance studies.
包括恶性疟原虫疟疾中对青蒿素耐药在内的抗疟药物耐药性是全球抗击疟疾的一个主要问题。寄生虫清除时间延迟(PCT)表明青蒿素耐药性的出现。在此,借助金标准技术显微镜并伴随一项更灵敏的实时检测方法对PCT进行监测,以用于学术目的。在给予基于青蒿素的联合疗法青蒿琥酯+磺胺多辛乙胺嘧啶(AS+SP)后,对所有受试者随访至第42天,以监测AS+SP在印度奥里萨邦孙德尔加尔区比斯拉社区卫生中心(CHC)的治疗效果。此外,对代表性样本分析恶性疟原虫ATP酶6(Pfatpase6)基因中的L263E、E431K、A623E和S769N单核苷酸多态性以及多重耐药蛋白1(Pfmdr1)基因中的拷贝数多态性。尽管到第3天结束时所有样本经显微镜检查均发现疟原虫阴性,且在第42天结束时达到了充分的临床和寄生虫学反应(ACPR),但实时聚合酶链反应(PCR)显示在总共分析的43个样本中有12个在第3天呈阳性。这通过终点诊断PCR进一步得到验证,并与高初始疟原虫载量相关。在这12个样本中有2个(16.7%)观察到E431K突变,而对照组(n = 18)均为野生型。在所有分析样本(n = 30)中,L263E、A623E和S769N均为野生型。Pfmdr1拷贝数分析显示该性状无变化。总之,实时PCR可为显微镜检查提供支持,以便更好地监测PCT,并可能作为青蒿素耐药性研究的一种额外但有用的研究工具。